DorsaVI   Report issue

For profit Phase 3
Founded: Melbourne Australia (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2014
NCT02205242
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

azithromycin (zithromax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1